Nanjing King-Friend Biochemical PharmaceuticalLtd Future Growth
Future criteria checks 5/6
Nanjing King-Friend Biochemical PharmaceuticalLtd is forecast to grow earnings and revenue by 70.5% and 25.5% per annum respectively. EPS is expected to grow by 72.7% per annum. Return on equity is forecast to be 17.3% in 3 years.
Key information
70.5%
Earnings growth rate
72.7%
EPS growth rate
| Pharmaceuticals earnings growth | 19.1% |
| Revenue growth rate | 25.5% |
| Future return on equity | 17.3% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?
Sep 30
Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)
Aug 26Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt
Jun 26Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult
May 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6,862 | 1,611 | N/A | 929 | 6 |
| 12/31/2025 | 5,636 | 1,216 | N/A | 590 | 7 |
| 12/31/2024 | 4,303 | 863 | N/A | 218 | 6 |
| 9/30/2024 | 3,877 | -423 | 853 | 1,503 | N/A |
| 6/30/2024 | 3,770 | -409 | 991 | 1,595 | N/A |
| 3/31/2024 | 3,628 | -345 | 1,269 | 1,698 | N/A |
| 12/31/2023 | 3,931 | -189 | 1,200 | 1,619 | N/A |
| 9/30/2023 | 4,004 | 1,023 | 829 | 1,135 | N/A |
| 6/30/2023 | 4,041 | 1,101 | 437 | 727 | N/A |
| 3/31/2023 | 3,844 | 1,093 | 142 | 466 | N/A |
| 12/31/2022 | 3,713 | 1,091 | 125 | 595 | N/A |
| 9/30/2022 | 3,758 | 1,122 | 494 | 1,069 | N/A |
| 6/30/2022 | 3,911 | 1,118 | 462 | 1,035 | N/A |
| 3/31/2022 | 3,980 | 1,116 | 376 | 929 | N/A |
| 12/31/2021 | 3,687 | 1,059 | 243 | 684 | N/A |
| 9/30/2021 | 3,537 | 1,038 | -163 | 242 | N/A |
| 6/30/2021 | 3,270 | 953 | -478 | -99 | N/A |
| 3/31/2021 | 3,064 | 875 | -820 | -469 | N/A |
| 12/31/2020 | 2,915 | 806 | -860 | -566 | N/A |
| 9/30/2020 | 2,800 | 770 | -869 | -761 | N/A |
| 6/30/2020 | 2,689 | 724 | -916 | -816 | N/A |
| 3/31/2020 | 2,594 | 660 | -850 | -744 | N/A |
| 12/31/2019 | 2,470 | 605 | -957 | -841 | N/A |
| 9/30/2019 | 2,224 | 539 | -711 | -553 | N/A |
| 6/30/2019 | 2,027 | 487 | -400 | -285 | N/A |
| 3/31/2019 | 1,875 | 452 | -279 | -184 | N/A |
| 12/31/2018 | 1,700 | 425 | -20 | 62 | N/A |
| 9/30/2018 | 1,633 | 425 | -171 | -85 | N/A |
| 6/30/2018 | 1,479 | 418 | N/A | -31 | N/A |
| 3/31/2018 | 1,325 | 380 | N/A | -142 | N/A |
| 12/31/2017 | 1,113 | 314 | N/A | -235 | N/A |
| 9/30/2017 | 915 | 276 | N/A | -268 | N/A |
| 6/30/2017 | 758 | 193 | N/A | -390 | N/A |
| 3/31/2017 | 668 | 284 | N/A | N/A | N/A |
| 12/31/2016 | 582 | 257 | N/A | -287 | N/A |
| 12/31/2015 | 469 | 88 | N/A | 137 | N/A |
| 12/31/2014 | 416 | 50 | N/A | 179 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603707 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 603707 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 603707 is expected to become profitable in the next 3 years.
Revenue vs Market: 603707's revenue (25.5% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 603707's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603707's Return on Equity is forecast to be low in 3 years time (17.3%).